Regeneron’s Met bet falls short
The Met x Met ADC REGN5093-M114 has been discontinued, but a Met x Met bispecific antibody remains.
AstraZeneca shores up its Tagrisso defences
The Hutchmed-originated savolitinib moves towards its first US approval.
ASCO 2024 preview – jury still out on AbbVie's cancer push
SEZ6 looks promising but early, while questions remain around toxicity with AbbVie's cMet ADCs.
AbbVie begins its Steap1 climb
Other projects new to the clinic include Haisco’s USP1 inhibitor and and Avistone’s type II c-MET blocker.
ESMO Asia 2023 – deaths raise doubts about Merus’s Rybrevant challenger
Merus still hopes for a future for MCLA-129, but the doors are closing.
